SureTrader Stock Hero Advertisement SPDR Advertisement
Home > Boards > Free Zone > User's Groups > Mohacsy's Safe Portfolio Member Forum

Orphan Drug Status doesn't assure FDA approval of

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
n4807g Member Profile
Member Level 
Followed By 32
Posts 27,723
Boards Moderated 0
Alias Born 07/08/03
160x600 placeholder
Advertisement
Morgan Stanley's Results Improve
Morgan Stanley's 1Q profit rose 59% to $2.39 billion as it benefited from busy markets and a flurry of corporate mergers. Revenue was $9.91 billion, or $9.78 billion excluding accounting adjustments. Results beat estimates. Shares up 1%.
More Top Equities Stories Of The Day
Myanmar Tin Exports Send Prices Lower
Wells Fargo Eyes GE Commercial Lender -- 2d Update
Morgan Stanley, New York in Talks to Settle Probe
Finland Likely to Elect New Government as Economy Wobbles
IBM Continues Painful Transition
European Prices Fall for Fourth Month
Yahoo, Microsoft Amend Terms to Terminate Search Deal
Semiconductor Startups Face the Flip Side of Moore's Law
n4807g Member Level  Monday, 04/23/12 12:16:00 PM
Re: FullBoogie post# 60301
Post # of 70074 
Orphan Drug Status doesn't assure FDA approval of the compound being evaluated, it confers certain marketing advantages and tax credits should the drug be approved.

Like most small biotechs CYTR will succeed or fail on the technology they employ. In CYTR's case the delivery system. The near term future of INNO-206 will be clear when they report interim findings of their ongoing 2b trial.

Like all biotechs this is a speculative investment, but I've watched many companies with similar strategies do well. The preliminary data look promising (no guarantee) but as I said in my previous post Abraxane uses Albumin as the entry vehicle in tumors and CYTR uses the same concept.

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist